一種新型軟件運(yùn)算法則使用了一種人工智能以及神經(jīng)網(wǎng)絡(luò)，并同時(shí)使用脈搏血氧測(cè)定儀，來(lái)檢測(cè)阻塞性睡眠暫停(OSA)和潮式呼吸（Cheyne-Stokes呼吸，CSR）。

這種技術(shù)是根據(jù)213項(xiàng)睡眠研究中血氧測(cè)定儀記錄到的分析結(jié)果而開(kāi)發(fā)的。已經(jīng)證實(shí)這套軟件在診斷OSA和CSR方面具有極高的敏感性和特異性。這項(xiàng)技術(shù)是由美國(guó)布法羅大學(xué)醫(yī)學(xué)與生物醫(yī)學(xué)科學(xué)院(UB, NY, USA)研制開(kāi)發(fā)的。OSA僅僅在美國(guó)就影響了180萬(wàn)人，同時(shí)還有90％患者沒(méi)有診斷出來(lái)。

布法羅大學(xué)已經(jīng)與Sleep解決方案公司(Annapolis, MD, USA)簽訂了一項(xiàng)協(xié)議，將這種新型檢測(cè)技術(shù)進(jìn)行商品化并投放市場(chǎng)。Sleep公司為這項(xiàng)新技術(shù)提供在家庭內(nèi)的診斷、治療以及監(jiān)護(hù)睡眠呼吸疾病（尤其式OSA）的服務(wù)。

根據(jù)布法羅大學(xué)研究部臨時(shí)副總裁 兼布法羅大學(xué)科學(xué)辦公室主任Robert J. Genco的說(shuō)法，“在全球范圍的臨床實(shí)踐中，對(duì)阻塞性睡眠暫停與潮式呼吸的診斷，迫切需要一種價(jià)廉物美的方法。我們十分自信Sleep公司將能夠把這種嶄新的技術(shù)投向市場(chǎng)，從而為大眾的需要提供低成本的操作簡(jiǎn)便的診斷公斤。”
 
New Testing Technology for Sleep Apnea
 
A new software algorithm uses a form of artificial intelligence, a neural network, to detect (OSA) and Cheyne-Stokes respiration (CSR), along with a pulse oximetry signal.

The technology is based on the analysis of the oximetric recordings of 213 sleep studies. The software has demonstrated very high sensitivities and specificities for diagnosing OSA and CSR.

The technology was developed at the University of Buffalo School of Medicine and Biomedical Sciences (UB, NY, USA). OSA affects 18 million people in the United States alone, with as many as 90% going undiagnosed.

The University of Buffalo has signed an agreement with Sleep Solutions, Inc. (Annapolis, MD, USA) to commercialize and distribute the new testing technology. Sleep Solutions provides technology and testing services for at-home diagnosis, therapy, and care of sleep-disordered breathing, particularly OSA.

According to Robert J. Genco, UB interim vice president for research and director of the UB Office of Science, there is “a growing worldwide clinical need to provide a cost-effective solution for diagnosis of obstructive sleep apnea and Cheyne-Stokes respiration. We are very confident that Sleep Solutions will be able to bring this novel technology to the marketplace resulting in a lower-costing, easier-to-implement diagnostic tool for the public good.”